Page 32 - Read Online
P. 32

METHODS                                             Table 1: EBV infection type

                                                              Infection      Anti‑EBV‑CA    Anti‑EBV‑ Anti‑EBNA
          Participants                                        type       IgG        IgM     EA IgG   IgG antibody
          A total of 20 patients with MS, of which 6 males and           antibody   antibody  antibody
          14 females were examined at Beijing Friendship Hospital   Acute   Low antibody  Positive  -  Negative
          from 2002 to 2010 and were enrolled in this study. MS   infection  affinity
                                                         [9]
          was defined using the 2010 McDonald criteria for MS.    Chronic   High antibody  -  Positive  Negative
                                                                         affinity
                                                              infection
          Among the patients, 14 had relapsing remitting MS, 2 had   Primary   Negative  -  Positive  Negative
          progressive remitting MS, 3 had primary progressive   infection
          MS, and 1 had secondary progressive MS. None of     Recurrence   High antibody  -  Positive  Positive
                                                              after infection affinity
          the patients had been treated with corticosteroids or   Past infection High antibody  -  Negative  Positive
          immunosuppressive agents 2 months before hospital              affinity
          admittance. Demographic data were collected from the   EBV: Epstein-Barr virus, CA: Capsid antigen, EA: Early antigen, IgG: Immunoglobulin G,
                                                              IgM: Immunoglobulin M, EBNA: Epstein–Barr nuclear antigen
          patients by retrospective review of their medical records.
                                                              Statistical analysis
          Twenty further patients were recruited with other   SPSS for Windows version 15.0 (SPSS Inc., Armonk, NY,
          neurological diseases  (OND), including 9 with      USA) was used for statistical analysis. The difference
                                                                                              2
          peripheral neuropathy, 4 with Parkinson’s disease, 2 with   between two means was tested by χ  and Fisher’s exact
          headache, 2 with neurosis, 2 with motor neuron disease   probability test. P < 0.05 was considered as statistically
          and 1 with cerebellar ataxia. Any OND patients with   significant.
          immunological diseases were excluded. There was no
          statistically significant difference (P > 0.05) in age and   RESULTS
          gender composition of the MS and OND patients.
                                                              Detection of CSF EBV related antibody in MS/OND patients
          This study was  approved  by  the  Capital Medical   Figure 1 shows the positive/negative reactions of
          University Affiliated Beijing Friendship Hospital Ethics   the  antibodies  of  anti-EBNA  IgG,  anti-EBV-CA  IgG,
          Committee. Written informed consents were obtained   anti-EBV-CA  IgM,  and  anti-EBV-EA  IgG.  The  anti-
          from individuals who participated in this study.    EBV-CA IgG antibody affinity is indicated in Figure 2.
                                                              There was no significant difference between MS and
          Anti‑EBV antibody assay                             OND patients whose CSF had antibodies of anti-EBNA
          The presence of anti-EBV antibodies, including      IgG, anti-EBV-EA IgG or anti-EBV-CA IgG (P > 0.05).
          anti-EBV-CA immunoglobulin G (IgG), anti-EBV-CA     However, there was a statistical difference between MS
          IgG affinity, anti-EBV-CA immunoglobulin M (IgM),   and OND patients whose CSF displayed high/low anti-
          anti-EBV early antigen (EBV-EA) IgG and anti-EBNA IgG,   EBV-CA IgG antibody affinity or positive anti-EBV-CA
          were assayed as described previously. Green florescence   IgM antibody (P < 0.05) [Table 2].
          indicated that CSF had related antigen-antibody (positive
          reaction). Anti-EBV-CA IgG antibody affinity was assayed   Composition of EBV infection type in MS and OND patients
          according to the green florescence intensity of urea-treated   The MS group had 15  patients who suffered from
          CSF parallel with physiological saline-treated CSF. [10]    EBV acute infection, while the OND group had only
          The intensity of florescence was depicted as follows: 0   5 patients. This difference between the groups was
          referred to no florescence, 1 to very weak florescence, 2 to   statistically significant. One patient in the MS group
          weak florescence, 3 to moderate florescence, 4 to strong   had a recurrence after an EBV infection, while this was
          florescence and 5 to very intense florescence. High   not detected in anyone in the OND group. EBV past
          antibody affinity indicated that the rate difference between   infection existed in 4 MS and 12 OND patients, which
          urea-treated CSF florescence intensity and physiological   was statistically different (P < 0.05). We failed to find
          saline-treated CSF florescence intensity was lower than   an EBV chronic or primary infection in either MS or
          two grades, while low antibody affinity was equal or   OND group.
          higher than two grades. Antibody affinity is unable to
          be assayed when florescence intensity of physiological   DISCUSSION
          saline-treated CSF is lower than two grades.
                                                              EBV is a ubiquitous human DNA herpes virus.
          The different EBV infection subtypes are shown in   More than 90% of the world’s population has been
          Table 1. [11]                                       infected with EBV. EBV infection is closely related to


          Neuroimmunol Neuroinflammation | Volume 1 | Issue 1 | June 2014                                   25
   27   28   29   30   31   32   33   34   35   36   37